Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{161954,
        author = {Shivani V. Mohite  and Dhanushree M. Gosavi and Rutuja S. Devkar and Ravi P. Barkade},
        title = {Hemolytic Disease of the Newborn (HDN)},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {7},
        pages = {139-144},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=161954},
        abstract = {Hemolytic disease of the Newborn (HDN), also known as Erythroblastosis fetalis, is a hemolytic condition that generally affects rhesus-positive fetuses and babies born to rhesus-negative mothers. The pathophysiology of HDN begins with motherly antibodies attacking fetal red blood cells following alloimmunization due to rhesus or ABO incompatibility between the motherly and fetal blood. Preliminarily, HDN was known to cause death in 1 of all pregnancies, but with the arrival of immunoprophylactic therapies condition can be presently fairly well managed with smaller complications if diagnosed beforehand. To help the disease, before intravenous immunoglobulin (IVIG) should be given to pregnant Rh- women who haven't sensitized. The diagnosis and management of pregnant women with HDN is premised on laboratory and radiographic monitoring. This review covers the disorder’s etiology, pathophysiology, and administration, as well as treatment and their management to help in unborn investigation and confirmation-based medical practice. },
        keywords = {ALLOIMMUNIZATION, HAEMOLYSIS, IMMUNOPROPHYLAXIS.},
        month = {},
        }